Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 5/20 | 1.00 |
| ▸ | CHRNA3 | P32297 | 5/20 | 1.00 |
| ▸ | CHRNA4 | P43681 | 5/20 | 1.00 |
| ▸ | CHRNB3 | Q05901 | 3/20 | 1.00 |
| ▸ | CHRNA6 | Q15825 | 3/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.54 |
| ▸ | TSHR | P16473 | 1/20 | 0.54 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.52 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | CHKA | P35790 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Piperazine SCHEMBL28221523 | 0.98 | CHRNB2 (0.95) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL1018088 | 0.98 | CHRNB2 (0.95) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL1706180 | 0.93 | CHRNB2 (0.87) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL26126254 | 0.92 | CHRNB2 (0.84) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL700886 | 0.92 | CHRNB2 (0.84) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL700681 | 0.92 | CHRNB2 (0.84) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL911817 | 0.91 | CHRNB2 (0.83) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL5455311 | 0.91 | CHRNB2 (0.83) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL911091 | 0.91 | CHRNB2 (0.83) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 | |
| SCHEMBL4714424 | 0.90 | CHRNB2 (0.81) | CHRNB2CHRNA3CHRNA4CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 641 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119504604-A | Method for preparing Olaparib by using sulfur hexafluoride | 国网安徽省电力有限公司电力科学研究院 | 2025-02-25 | — | — | CN | claimed |
| US-20240351989-A1 | PROCESS FOR THE PREPARATION OF OLAPARIB, AND CRYSTALLINE FORM THEREOF | ALIVUS LIFE SCIENCES LIMITED (IN) | 2024-10-24 | — | — | US | claimed |
| CN-118359545-A | Preparation method of Olaparib monohydrate | 杭州中美华东制药有限公司 | 2024-07-19 | — | — | CN | claimed |
| CN-111116514-B | Preparation method of 1-cyclopropanecarbonyl piperazine hydrochloride | 广州科锐特生物科技有限公司 | 2024-03-19 | — | — | CN | claimed |
| CN-112341580-B | Preparation method of polyacetal composition with high thermal stability | 青岛聚合利安工程技术有限公司 | 2022-11-11 | — | — | CN | claimed |
| CN-112500379-A | Olapari intermediate and preparation method of Olapari | 南京方生和医药科技有限公司 | 2021-03-16 | — | — | CN | claimed |
| CN-112341580-A | Preparation method of polyacetal composition with high thermal stability | 青岛聚合利安工程技术有限公司 | 2021-02-09 | — | — | CN | claimed |
| CN-108129397-B | Synthetic method of olaparib | 北京耀诚惠仁科技有限公司 | 2020-11-06 | — | — | CN | claimed |
| CN-110790710-A | Synthetic method of olaparib | 东南大学 | 2020-02-14 | — | — | CN | claimed |
| CN-110078671-A | The preparation method of olaparib | 江苏君若医药有限公司 | 2019-08-02 | — | — | CN | claimed |
| EP-2779217-A2 | Chemical mechanical planarization for tungsten-containing substrates | AIR PRODUCTS AND CHEMICALS, INC. (US) | 2014-09-17 | — | — | EP | claimed |
| WO-2013092941-A1 | BENZYL SULFONAMIDE DERIVATIVES AS RORc MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2013-06-27 | — | — | WO | claimed |
| US-8247416-B2 | Phthalazinone derivative | KUDOS PHARMACEUTICALS LIMITED (GB) | 2012-08-21 | — | — | US | claimed |
| CN-102627611-A | Polymorphic form of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | KUDOS PHARM LTD | 2012-08-08 | — | — | CN | claimed |
| EP-2374800-A2 | Methods for the preparation of 4-[3-(4-cyclopropanecarbonyl- piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one | Kudos Pharmaceuticals Limited (GB) | 2011-10-12 | — | — | EP | claimed |
| US-20090270617-A1 | PHTHALAZINONE DERIVATIVE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-10-29 | — | — | US | claimed |
| CN-101528714-A | Polymorphs of 4- [ 3- (4-cyclopropanecarbonyl-piperazine-1-carbonyl) -4-fluoro-benzyl ] -2H-phthalazin-1-one | KUDOS PHARM LTD (GB) | 2009-09-09 | — | — | CN | claimed |
| EP-2064189-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | Kudos Pharmaceuticals Limited (GB) | 2009-06-03 | — | — | EP | claimed |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-06-19 | — | — | US | claimed |
| WO-2008047082-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240351989-A1 | PROCESS FOR THE PREPARATION OF OLAPARIB, AND CRYSTALLINE FORM THEREOF | PARP1, PARP2, PARP4 | CHRNB2 4524/4885CHRNA3 4451/4885CHRNA4 4313/4885 |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | PARP1, PARP11, PARP2 | CHRNB2 4356/4885CHRNA3 4141/4885CHRNA4 4242/4885 |
| US-20090270617-A1 | PHTHALAZINONE DERIVATIVE | PML, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA4 | CHRNB2 4159/4885CHRNA3 3826/4885CHRNA4 3319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.